Amal Therapeutics Exit

Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic cargo.


Dr. Madiha Derouazi

Press releases

AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round

Second closing of Series B raises €21.2 million (CHF 24.2 million) Funding to support clinical development of lead vaccine and extension of KISIMA® technology platform Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund with VI Partners, Schroder Adveq and…

Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund

Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss…

Amal Therapeutics SA raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds to develop therapeutic cancer vaccines based on its proprietary technology platform

Amal Therapeutics SA, a Geneva and Berlin-based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-penetrating peptide based technology platform and progress the first vaccine candidate up to…

Info & Contact


Avenue de la Roseraie 64
1205 Geneva

In portfolio

07. Feb 2014 – 28. Jun 2019